63 results about "Instilling eye drops" patented technology

The present invention relates to a vitamin A liposome artificial tears eye drops for preventing and curing xerophthalmia and ophthalmokopia. Its composition includes fat-soluble vitamin A, liposome encapsulating material, vitamin E and artificial tears hydrated liquor, in which the fat-soluble vitamin A is vitamin A palmitate or vitamin A acetate, the liposome encapsulating material is soya bean lecithin and cholesterol, and the composition of artificial tears hydrated liquor includes sodium hydrogen carbonate, sodium chloride, glucose, potassium chloride, calcium chloride and water. Besides, according to requirements one or several kinds of auxiliary components of menthanol, PVP and HPMC, etc. also can be added.

Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

The present invention discloses a composition capable of enhancing the drug safety and clinical efficacy of low concentration atropines, and especially when the composition is used in low concentration atropines eye drops, the fact that the composition used in the low concentration atropines eye drops provided by the invention can effectively improve the drug safety of low concentration atropinesby adjusting key quality parameters such as pH, osmotic pressure and viscosity of the eye drops is creatively discovered, especially for improving clinical efficacy, so as to effectively solve the problems in the use of current low-concentration atropines eye drops, such as poor safety, large efficacy differences, unstable main drugs, safety of impurities degradation, concomitant adverse reactionsand other side effects. The composition enhances the clinical efficacy of low concentration atropines eye drops in the prevention and treatment of myopia of adolescents and children and provides a safer and healthier guarantee for the eyesight of adolescents and children, and has a very broad application prospect.

The present invention provides an ophthalmic solution containing pranoprofen or a pharmacologically acceptable salt thereof, and a vasoconstrictor, which is effective for ameliorating congestion in outer ocular areas, particularly conjunctiva and pericorneal area.

The invention discloses a steroid compound and pharmaceutically acceptable salt thereof, and a preparation method and application thereof. The structural formula of the steroid compound is shown as a formula I ', in the formula I', R is dimethylamino or methylamino, and the eye drops taking the compound (SZY1906-P22) of the formula I with R being dimethylamino as an active ingredient can reduce the lens opacity of New Zealand rabbits with spontaneous senile cataract.

The invention discloses a nutritious supplement for improving eyesight and a preparation method and application thereof. Raw materials of the nutritious supplement comprise mulberries, radix rehmanniae preparata, semen astragali complanati, fructus lycii, semen euryales, semen cassiae, fructus schisandrae chinensis, semen plantaginis, flos buddlejae, flos tagetis erectae, ginseng and fructus ligustri lucidi. The invention also provides the preparation method and application of the nutritious supplement. The nutritious supplement can be used for preparing an oral or external preparation for improving the eyesight. Preferably, the oral preparation is added into a dairy beverage and mixed uniformly for drinking. The external preparation is used as an eye drop. The nutritious supplement for improving the eyesight and the preparation method and application thereof have the advantages of reasonable formula, small dosage, obvious effect and the like. The Chinese medicinal essence is extracted, preparation is convenient and easy to achieve, the cost is low, the healing rate is high, and the preparation is safe and free of toxic and side effects and can avoid generation of drug resistance and achieve the effect of fundamentally improving the eyesight.

The invention discloses cetirizine hydrochloride ophthalmic liposome, in-situ gel and a preparation method of cetirizine hydrochloride ophthalmic liposome, and belongs to the technical field of pharmaceutical preparations. In order to overcome the defects that existing cetirizine hydrochloride eye drops are short in residence time, poor in compliance of semi-solid dosage forms, low in bioavailability, not easy to accept by patients and the like, an ethanol injection method is combined with an ammonium sulfate gradient method to obtain the liposome, and the liposome comprises 0.28-0.30% of cetirizine hydrochloride, 1.4-6.0% of phospholipid, 0.14-1.8% of cholesterol, 0.1-0.15% of an osmotic pressure regulator, 0.05-0.1% of a bacteriostatic agent and the balance of water. And a solvent. The invention further provides the cetirizine hydrochloride liposome-in-situ gel and a preparation method thereof. By optimizing the prescription and the process, the obtained liposome and in-situ gel can delay the drug release, increase the retention time of eyes, improve the cornea permeability and improve the bioavailability.

The invention discloses loteprednol etabonate suspension eye drops. The loteprednol etabonate suspension eye drops contain loteprednol etabonate as an active component, water and one or more accessory materials for suspension eye drops. The used loteprednol etabonate micro-powder meets the particle size distribution conditions comprising that D50 is in a range of 3.0-4.0 microns, the maximum particle size is less than 30 microns, a ratio of micro-powder particles having sizes of 1-8 microns is in a range of 79-85%, and a ratio of micro-powder particles having sizes of 1-4 microns is in a range of 49-56%.

The invention relates to the technical field of medical materials, in particular to oxidized sodium alginate modified natamycin eye drops and a preparation method thereof. The oxidized sodium alginate modified natamycin eye drops has the component and content that 1 mL of sterilized deionized water contains 0.5-1.5 mg of oxidized sodium alginate-natamycin freeze-dried powder; the oxidized sodium alginate-natamycin is a product obtained by carrying out a Schiff base reaction on oxidized sodium alginate and natamycin; the preparation method comprises the following specific steps: preparing oxidized sodium alginate solid, preparing oxidized sodium alginate-natamycin medicine powder, and preparing the eye drops. The property of the oxidized sodium alginate is similar to that of a human extracellular matrix, so that the oxidized sodium alginate is good in histocompatibility and can be degraded into non-toxic polysaccharide which does not participate in metabolism; the water solubility and permeability of the natamycin are improved, the eye irritation and discomfort of the natamycin are reduced, and the treatment effect of the fungal keratitis is improved; the preparation process is relatively simple, low in cost and easy to store.

The invention discloses an application of a polypeptide in a medicine for treating eye inflammation. The amino acid sequence of the polypeptide is YGRKKRRQRRRMMPYSTELIFYIEMDP. Eye drops prepared fromthe polypeptide comprise the following components in percentage by weight: 0.05-1% of polypeptide, and the eye inflammation is conjunctivitis, keratitis and/or uveitis. In the polypeptide eye drops, the pharmacological action of the polypeptide in treatment of inflammation is to inhibit inflammation from participating in cell proliferation, inhibit NF-kB activation, inhibit the generation and secretion of various inflammatory mediators, inhibit the growth of new capillaries, inhibit the aggregation and infiltration of inflammatory cells and the like. The polypeptide eye drops are clear in pharmacology, good in curative effect, low in side effect, stable in biological activity of bulk drugs, simple in production process, low in cost and beneficial to large-scale clinical application and reduction of burden of patients.

The invention discloses application of bortezomib and preparation of bortezomib to preparation of a medicine for treating choroidal neovascularization related diseases and a preparation method of eyedrops. A protease complex inhibitor bortezomib is injected into a vitreous cavity or bortezomib eye drops are used on the ocular surface, the bortezomib and the preparation of bortezomib can be used for treating choroidal neovascularization related fundus diseases such as treatment of wet age-related macular degeneration, the side effect is small, and the curative effect is good.

The invention relates to traditional Chinese medicine effective components for treating eye diseases, and a composition thereof. The composition contains the effective components including aesculin and aesculin. The invention breaks through the conventional cognition in the field, clarifies the actual effective components and pharmacological action of the Qin ice eye drops, verifies that the composition is stable in action effect and clear in action mechanism, can inhibit the expression of lymphatic neogenesis related factors and inflammatory factors in macrophages, the growth of methicillin-resistant staphylococcus aureus MRSA and pseudomonas aeruginosa PA14 is inhibited, and lymphatic vessel neogenesis caused by mouse corneal alkali burn is inhibited, so that the traditional Chinese medicine effective components and the composition can be used for treating lymphatic vessel neogenesis, inflammation and immune-related eye diseases.

The present invention relates to Chinese medicine, and is especially one kind of eye drop for treating eye diseases and its preparation process. The Chinese medicine is prepared with sesame oil, scorpion, centipede and earth worm and through special technological process. It has wide treating range, and may be used in treating cornea disease, iritis and secondary glaucoma, and has high effective rate and no toxic side effect and drug fastness.

The invention relates to a drug effective ingredient, in particular to a nimodipine (NMD) ophthalmic preparation and a preparation method thereof. The nimodipine ophthalmic preparation comprises a medicinal auxiliary and an effective quantity of nimodipine ingredient used for protecting optic nerves and dispersed to the auxiliary. In the embodiment of the invention, the NMD ophthalmic preparation comprises a 0.09% NMD eye drop and a 0.3% NMD eye ointment. The preparation method of the 0.09% NMD eye drop comprises the following steps of: adding 0.9 g of NMD and 0.3 g of ethylparaben into 50 ml of tween-80, and uniformly stirring, adding 600 ml of double buffer solution, heating to dissolve, adding the double buffer solution to 1000 ml, and adjusting the pH value to 6.7-7.2; filtering, sterilizing by flowing stream, and canning. The preparation method of the 0.3% NMD eye ointment comprises the following steps of: placing 3g of nimodipine in a sterilizing mortar in sterile operation, adding 5 ml of sterilized liquid paraffin, grinding into a fine paste, adding into 0.3g of ethylparaben and 50 ml of tween-80, uniformly stirring, adding an eye ointment matrix several times, uniformly grinding while adding till being 1000g, and subpackaging in a sterile way. The nimodipine ophthalmic preparation has the advantages of high efficiency, small side effect and convenient medication, and has good application prospect in the prevention and treatment of eye diseases, especially the protection of glaucoma optic nerves.

The invention discloses a medicinal preparation for treating chronic conjunctivitis. The medicinal composition comprises pearl, astragalus and other traditional Chinese medicines, and eye drops can be prepared from the medicinal composition according to clinical requirements. The medicinal composition has an excellent effect for treating or relieving symptoms of chronic conjunctivitis, asthenopia and ocular dryness.

The invention provides a pharmaceutical application of amniotic epithelial cell conditioned medium eye drops, an application of the amniotic epithelial cell conditioned medium in preparation of the eye drops and an application of the amniotic epithelial cell conditioned medium in preparation of drugs for allergic conjunctivitis. The invention also discloses a preparation method of the amniotic epithelial cell conditioned medium eye drops. According to the pharmaceutical application of the amniotic epithelial cell conditioned medium eye drops, it is found and proved for the first time that the conditioned medium derived from human amniotic epithelial cells can inhibit allergic conjunctivitis. When the amniotic epithelial cell conditioned medium eye drops are used for treating conjunctivitis allergic conjunctivitis, the immunogenicity is low, direct use of cells is avoided, and the amniotic epithelial cell conditioned medium eye drops are safe, effective and high in product stability.

The invention relates to the technical field of medicines, in particular to application of exenatide to preparation of medicines for treating ocular ischemia diseases and improving ocular blood circulation in an eye drip way. The exenatide can be used for treating the ocular ischemia diseases such as onset of acute glaucoma and improving the ocular blood circulation . According to the applicationdisclosed by the invention, through building an acute ischemia reperfusion model and simulating damage of the onset of the acute glaucoma, findings prove that an eye drop preparation of Exendin-4 canimprove a retinal vascular endothelial function, dilating retinal capillary and recovering fundus blood circulation, so that the damage to the fundus blood supply caused by the ocular ischemia diseases such as acute glaucoma can be effectively alleviated, and simultaneously, the findings prove that a new medicine dosage form (eye drop preparation) can achieve an effective local action under the premise of avoiding systemic action. The exenatide disclosed by the invention can be used for treating deficiency of the fundus blood supply such as the acute glaucoma, retinopathy of prematurity and retinal vascular occlusion diseases, and thus, the visual function is saved.

The present invention relates to an ophthalmic solution of lissamine green which has shown to be particularly stable over time and well tolerated by the eye. Therefore, the ophthalmic solution finds advantageous application in the diagnosis of corneal and conjunctival anomalies.